Lori J. Wirth
Experienced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Lori J. Wirth

Oncology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lori Wirth is an Oncologist in Boston, Massachusetts. Dr. Wirth is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Thyroid Cancer, Medullary Thyroid Carcinoma, Papillary Thyroid Cancer, Tissue Biopsy, and Thyroidectomy. Dr. Wirth is currently accepting new patients.

Her clinical research consists of co-authoring 157 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles and participated in 2 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Massachusetts Eye And Ear Infirmary -
North Shore Medical Center -
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Options
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114
Other Locations
THE GENERAL HOSPITAL CORPORATION
102 Endicott St, Danvers, MA 01923

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drugs: Decitabine, Durvalumab
Study Phase: Phase 1
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Selumetinib, Iodine-131
Study Phase: Phase 2
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Biological
Study Drugs: Autologous Epstein Barr Virus-Specific Cytotoxic T Cells, Gemcitabine, Carboplatin
Study Phase: Phase 3
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Enrollment Status: Completed
Publish Date: October 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
Enrollment Status: Completed
Publish Date: May 25, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 10 Less Clinical Trials

157 Total Publications

Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review.
Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review.
Journal: JAMA oncology
Published: September 25, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Justin F. Gainor
Oncology | Hematology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Justin F. Gainor
Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Gainor is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Gainor is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Gainor is currently accepting new patients.

Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Lecia V. Sequist
Oncology | Hematology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Lecia V. Sequist
Oncology | Hematology

The General Hospital Corporation

40 2nd Ave, 
Waltham, MA 
 (10.3 miles away)
781-487-2900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lecia Sequist is an Oncologist and a Hematologist in Waltham, Massachusetts. Dr. Sequist is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Sequist is currently accepting new patients.

Geoffrey R. Oxnard
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Geoffrey R. Oxnard
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Geoffrey R. Oxnard
Oncology

Evans Medical Foundation Inc

88 E Newton St, Evans 124, 
Boston, MA 
 (1.8 miles away)
617-638-6500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Geoffrey Oxnard is an Oncologist in Boston, Massachusetts. Dr. Oxnard is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Oxnard is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wirth's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 9 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile